Date:11/2/2010

tock options1,941647Excess tax benefit of stock transactions(9,465)(2,430)Deferred income taxes(59,069)(12,752)   Sub-total34,90070,472   Changes in operating assets and liabilities, net of asset and businessacquisitions Accounts receivable(58,401)(23,901)Inventories(3,559)(3,408)Income taxes refundable12,6682,653Accounts payable(9,636)(29,907)Payroll and related taxes(21,191)3,468Accrued customer programs11,2015,769Accrued liabilities(12,899)(4,497)Accrued income taxes36,48420,524Other4,271(4,816)   Sub-total(41,062)(34,115)Net cash (for) from operating activities(6,162)36,357Cash Flows (For) From Investing Activities   Acquired research and development-(14,000)   Acquisition of business - purchase price adjustment1,998-   Acquisition of business, net of cash acquired-(10,059)   Additions to property and equipment(9,194)(7,515)   Acquisitions of assets-(5,110)Net cash for investing activities(7,196)(36,684)Cash Flows (For) From Financing Activities   Repayments of short-term debt, net(7,476)-   Repayments of long-term debt(95,000)(50,000)   Net borrowings under accounts receivable securitization program63,000-   Excess tax benefit of stock transactions9,4652,430   Issuance of common stock3,9873,620   Repurchase of common stock(8,168)(25,286)   Cash dividends(5,780)(5,106)Net cash for financing activities(39,972)(74,342)Effect of exchange rate changes on cash(337)997Net decrease in cash and cash equivalents(53,667)(73,672)Cash and cash equivalents of continuing operations, beginning of period109,765317,638Cash balance of discontinued operations, beginning of period-4Cash and cash equivalents, end of period56,098243,970Less cash balance of discontinued operations, end of period-(5)Cash and cash equivalents of continuing operations, end of period

$

56,098$

243,965Supplemental Disclosures of Cash Flow Information   Cash paid/received during the period for:Interest paid<
'/>"/>

SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Perrigo Company Announces Dividend Increase
2. Perrigo Company Will Release First Quarter Fiscal 2011 Results on November 2, 2010
3. Perrigo Confirms Filing for Omeprazole/Sodium Bicarbonate and Announcement of Patent Infringement Lawsuit by Schering-Plough Healthcare Products
4. Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
5. Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
6. Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup
7. Perrigo Company Confirms Patent Challenge for Clobetasol Propionate Emulsion Foam
8. Perrigo Acquires Exclusive Sales and Distribution Rights to OTC Store Brand Versions of Allegra® and Allegra D-12 From Teva
9. Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference
10. Perrigo Company to Present at the 31st Annual Goldman Sachs Global Healthcare Conference
11. Perrigo Announces FDA Final Approval for Miconazole